These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21710244)

  • 21. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
    Bensmaïne MA; Marty M; de Gramont A; Brienza S; Lévi F; Ducreux M; François E; Gamelin E; Bleiberg H; Cvitkovic E
    Br J Cancer; 2001 Aug; 85(4):509-17. PubMed ID: 11506488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxidative Stress-Induced Damage to RNA and DNA and Mortality in Individuals with Psychiatric Illness.
    Jorgensen A; Brandslund I; Ellervik C; Henriksen T; Weimann A; Andersen MP; Torp-Pedersen C; Andersen PK; Jorgensen MB; Poulsen HE
    JAMA Psychiatry; 2024 May; 81(5):516-520. PubMed ID: 38446448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Markers of oxidative stress in obese men with and without hypertension.
    Cejvanovic V; Asferg C; Kjær LK; Andersen UB; Linneberg A; Frystyk J; Henriksen T; Flyvbjerg A; Christiansen M; Weimann A; Jeppesen J; Poulsen HE
    Scand J Clin Lab Invest; 2016 Dec; 76(8):620-625. PubMed ID: 27666677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).
    Innominato PF; Giacchetti S; Moreau T; Smaaland R; Focan C; Bjarnason GA; Garufi C; Iacobelli S; Tampellini M; Tumolo S; Carvalho C; Karaboué A; Lévi F;
    Chronobiol Int; 2011 Aug; 28(7):586-600. PubMed ID: 21859417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
    Seki H; Ozaki T; Shiina M
    Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.
    Kho Y; Jansman FG; Prins NH; Neef C; Brouwers JR
    Ther Drug Monit; 2006 Apr; 28(2):206-11. PubMed ID: 16628132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated levels of 8-oxoGuo and 8-oxodG in individuals with severe mental illness - An autopsy-based study.
    Christensen MR; Poulsen HE; Henriksen T; Weimann A; Ellervik C; Lynnerup N; Rungby J; Banner J
    Free Radic Biol Med; 2018 Oct; 126():372-378. PubMed ID: 30145229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX.
    Mori Y; Nishimura T; Kitano T; Yoshimura K; Matsumoto S; Kanai M; Hazama M; Ishiguro H; Nagayama S; Yanagihara K; Teramukai S; Chiba T; Sakai Y; Fukushima M
    Oncology; 2010; 79(1-2):136-43. PubMed ID: 21150228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Role of sequential chemotherapy in the treatment of metastatic colorectal cancer].
    Tassinari D; Tamburini E; Carloni F; Nicoletti S; Ravaioli A
    Recenti Prog Med; 2009 Feb; 100(2):73-9. PubMed ID: 19350798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early life low-level cadmium exposure is positively associated with increased oxidative stress.
    Kippler M; Hossain MB; Lindh C; Moore SE; Kabir I; Vahter M; Broberg K
    Environ Res; 2012 Jan; 112():164-70. PubMed ID: 22192840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
    Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
    Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.
    Kallen KJ; Hofmann MA; Timm A; Gödderz W; Galle PR; Heike M
    Z Gastroenterol; 2000 Feb; 38(2):153-7. PubMed ID: 10721170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous determination of 8-oxo-2'-deoxyguanosine and 8-oxo-2'-deoxyadenosine in DNA using online column-switching liquid chromatography/tandem mass spectrometry.
    Singh R; Teichert F; Verschoyle RD; Kaur B; Vives M; Sharma RA; Steward WP; Gescher AJ; Farmer PB
    Rapid Commun Mass Spectrom; 2009 Jan; 23(1):151-60. PubMed ID: 19065576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
    Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
    J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
    Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
    Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical relevance of guanine-derived urinary biomarkers of oxidative stress, determined by LC-MS/MS.
    Shih YM; Cooke MS; Pan CH; Chao MR; Hu CW
    Redox Biol; 2019 Jan; 20():556-565. PubMed ID: 30508700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.